ADVFN Logo ADVFN
市場データ
ニュース
投資ツール
市場
発見

Hot Features

Follow Feed

フォローフィードコミュニティでトレーダーや投資家とつながりましょう.

ライブオプションフロー

包括的なオプション データを調査し、オプション フローで高度なフィルターを使用します.

モニター

ターミナル モニターで株式と資産のウォッチリストを整理および監視します
サインイン Premium Iconプレミアム Help Menu
Bitcoin
62,341.93
-1.31%
S&P 500
5,187.70
0.13%
Dow Jones
38,884.26
0.08%
US Dollar vs Yen
154.792
0.36%
Brent Oil
82.865
-0.73%
Registration Strip Icon for default 登録して無料でリアルタイムの株価、インタラクティブチャート、ライブオプションフローなどを入手してください。
登録
  1. ホーム
  2. 投資
  3. 株式
  4. アメリカ
  5. NASDAQ
  6. Spero Therapeutics Inc (SPRO)

  7. Spero Therapeutics Inc (SPRO) ニュース

SPRO

Spero Therapeutics (SPRO)

Spero Therapeutics Inc
から:
次の項目別のソート:
 Showing the most relevant articles for your search:NASDAQ:SPRO
日付受信時刻ニュースソース見出しコード企業名
2024/03/0622 : 05GlobeNewswire Inc.Spero Therapeutics to Provide Business Update and Report Fourth Quarter and Full Year 2023 Financial Results on Wednesday, March 13, 2024NASDAQ:SPROSpero Therapeutics Inc
2024/02/2822 : 05GlobeNewswire Inc.Spero Therapeutics Announces Clearance of IND for SPR206 to Treat MDR Gram-negative Bacterial InfectionsNASDAQ:SPROSpero Therapeutics Inc
2024/02/2622 : 05GlobeNewswire Inc.Spero Therapeutics to Present at Cowen’s 44th Annual Healthcare ConferenceNASDAQ:SPROSpero Therapeutics Inc
2024/02/1006 : 05Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:SPROSpero Therapeutics Inc
2024/02/0610 : 53Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:SPROSpero Therapeutics Inc
2024/02/0610 : 50Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:SPROSpero Therapeutics Inc
2024/02/0610 : 45Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:SPROSpero Therapeutics Inc
2024/02/0610 : 44Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:SPROSpero Therapeutics Inc
2024/02/0610 : 40Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:SPROSpero Therapeutics Inc
2024/02/0606 : 50Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:SPROSpero Therapeutics Inc
2024/02/0106 : 05GlobeNewswire Inc.Spero Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:SPROSpero Therapeutics Inc
2024/01/0820 : 07Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:SPROSpero Therapeutics Inc
2024/01/0522 : 11Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:SPROSpero Therapeutics Inc
2024/01/0522 : 05GlobeNewswire Inc.Spero Therapeutics Provides Corporate Update and 2024 OutlookNASDAQ:SPROSpero Therapeutics Inc
2024/01/0506 : 40Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:SPROSpero Therapeutics Inc
2024/01/0222 : 13Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:SPROSpero Therapeutics Inc
2024/01/0222 : 05GlobeNewswire Inc.Spero Therapeutics Announces First Patient, First Visit for Phase 3 PIVOT-PO Trial Evaluating Tebipenem HBr in Complicated Urinary Tract InfectionsNASDAQ:SPROSpero Therapeutics Inc
2023/11/1606 : 17Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:SPROSpero Therapeutics Inc
2023/11/1606 : 15Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:SPROSpero Therapeutics Inc
2023/11/1406 : 50Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:SPROSpero Therapeutics Inc
2023/11/1406 : 45Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:SPROSpero Therapeutics Inc
2023/11/1406 : 13Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:SPROSpero Therapeutics Inc
2023/11/1406 : 05GlobeNewswire Inc.Spero Therapeutics Announces Third Quarter 2023 Operating Results and Provides a Business UpdateNASDAQ:SPROSpero Therapeutics Inc
2023/11/1406 : 02Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:SPROSpero Therapeutics Inc
2023/11/1320 : 45IH Market NewsMonday’s Wall Street Highlights: Boeing, Novo Nordisk, Moody’s, StoneCo, and moreNASDAQ:SPROSpero Therapeutics Inc
2023/11/0622 : 05GlobeNewswire Inc.Spero Therapeutics to Provide Business Update and Report Third Quarter 2023 Financial Results on Monday, November 13, 2023NASDAQ:SPROSpero Therapeutics Inc
2023/11/0205 : 05GlobeNewswire Inc.Spero Therapeutics to Present at Upcoming November Investor ConferencesNASDAQ:SPROSpero Therapeutics Inc
2023/11/0121 : 10Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:SPROSpero Therapeutics Inc
2023/11/0121 : 05GlobeNewswire Inc.Spero Therapeutics Appoints Esther Rajavelu as Chief Financial Officer and Chief Business OfficerNASDAQ:SPROSpero Therapeutics Inc
2023/11/0105 : 05GlobeNewswire Inc.Spero Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:SPROSpero Therapeutics Inc
 Showing the most relevant articles for your search:NASDAQ:SPRO

最近閲覧した銘柄

NASDAQ
MSFT
Microsoft
NYSE
DIS
Walt Disney
NYSE
AXP
American Express
AMEX
XLF
Financial Select Sector
AMEX
SPY
SPDR S&P 500
USI
USTECH100
US Tech 100
PM
XAUUSD
Gold vs US Dollar
NASDAQ
GOOGL
Alphabet
COIN
SOLUSD
Solana
NASDAQ
AAPL
Apple
NYSE
XOM
Exxon Mobil
CCOM
US500
US 500
SPI
SP500
S&P 500
AMEX
XLV
Health Care Select Sector
CCOM
US100
US Tech 100
Delayed Upgrade Clock
ADVFN Logo

日本
会社情報
ビジネス
人気
アプリを入手

顧客サポート: +44 (0) 203 8794 460 | support@advfn.com

ADVFNのサービスをご利用いただくには、利用規約

© 2024 ADVFN PLC - 全著作権所有